Regulatory barriers to opioid analgesic access in Kazakhstan

Discover Health Systems, 2026

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.1007/s44250-026-00406-y
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Abstract This article presents a comprehensive analysis of the regulatory framework and administrative procedures affecting the availability of opioid analgesics for palliative care patients in the Republic of Kazakhstan. Based on an examination of national legislation, subordinate regulations, and their implementation in medical and pharmaceutical organizations, the study identifies key regulatory barriers: mandatory use of paper prescription forms of strict accountability, a limited network of pharmacies licensed to dispense controlled medicines, duplication of procedures for authorizing medical personnel, and burdensome interagency paper-based correspondence. Special attention is paid to inconsistencies between existing legal provisions and their practical implementation. These inconsistencies lead to delays in providing patients with adequate pain relief and reduce the effectiveness of palliative care. The article proposes directions for improving the regulatory framework and administrative procedures in the context of ongoing digitalization of the healthcare system.